Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Fidler S., Fox J., Tipoe T., Longet S., Tipton T., Abeywickrema M., Adele S., Alagaratnam J., Ali M., Aley PK., Aslam S., Balasubramanian A., Bara A., Bawa T., Brown A., Brown H., Cappuccini F., Davies S., Fowler J., Godfrey L., Goodman AL., Hilario K., Hackstein CP., Mathew M., Mujadidi YF., Packham A., Petersen C., Plested E., Pollock KM., Ramasamy MN., Robinson H., Robinson N., Rongkard P., Sanders H., Serafimova T., Spence N., Waters A., Woods D., Zacharopoulou P., Barnes E., Dunachie S., Goulder P., Klenerman P., Winston A., Hill AVS., Gilbert SC., Carroll M., Pollard AJ., Lambe T., Ogbe A., Frater J.
BACKGROUND: People with HIV on antiretroviral therapy with good CD4 T cell counts make effective immune responses following vaccination against SARS-CoV-2. There are few data on longer term responses and the impact of a booster dose. METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed twelve months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µl. Immune responses to the ancestral strain and variants of concern were measured by anti-spike IgG ELISA, MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, Activation Induced Marker (AIM) assay and T cell proliferation. FINDINGS: 54 participants received two doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) one year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titres (MSD), ACE-2 inhibition and IgG ELISA results were significantly higher compared to Day 182 titres (P